Published in 2016 – Ann Oncol (2016) 27 (suppl 5): v119-v133
Authors: F. Roila, A. Molassiotis, J. Herrstedt, M. Aapro, R. J. Gralla, E. Bruera, R. A. Clark-Snow, L. L. Dupuis, L. H. Einhorn, P. Feyer, P. J. Hesketh, K. Jordan, I. Olver, B. L. Rapoport, J. Roscoe, C. H. Ruhlmann, D. Walsh, D. Warr and M. van der Wetering
Despite the considerable progress achieved in the last 30 years, vomiting and, especially, nausea, continue to be two of the most distressing side-effects of cancer chemotherapy.
The European Society for Medical Oncology and the Multinational Association of Supportive Care in Cancer have produced updated, joint guidelines as a follow-up to
consensus guidelines that were originally published in 2010. An update of the original recommendations, results of a consensus conference on antiemetics held in Perugia in June 2009, include studies published from 1 January 2009 to 30 June 2015, that were discussed at a consensus conference in Copenhagen in June 2015. The guidelines on antiemetics provide an update on the classification of the emetogenic potential of antineoplastic agents, adding 42 new drugs many of which are orally administered. The recommendations for the prophylaxis of nausea and vomiting induced by different chemotherapeutic agents have also been updated.